Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516965 | 0.79 | ACHE (0.33) | — | |
| SCHEMBL5241664 | 0.77 | CYP3A4 (0.46) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL2284180 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL30181273 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL1085636 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL9229801 | 0.75 | CYP3A4 (0.39) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL3867828 | 0.75 | ALDH1A1 (0.39) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3213353 | 0.73 | ALDH1A1 (0.37) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL23153960 | 0.71 | CYP3A4 (0.36) | ALDH1A1CYP3A4TSHRPIK3CATDP1 | |
| SCHEMBL9293416 | 0.71 | CYP3A4 (0.38) | ALDH1A1CYP3A4TSHRPIK3CATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| CN-102695704-A | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS INC | 2012-09-26 | — | — | CN | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | ALDH1A1 2672/4885CYP3A4 1375/4885TSHR 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.